Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 14/20 | 0.64 |
| ▸ | IKBKB | O14920 | 3/20 | 0.57 |
| ▸ | JAK2 | O60674 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | JAK3 | P52333 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928818 | 0.89 | IKBKB (0.55) | CHEK1IKBKBJAK2MEN1KMT2A | |
| SCHEMBL1928275 | 0.89 | IKBKB (0.55) | CHEK1IKBKBJAK2MEN1KMT2A | |
| SCHEMBL1928820 | 0.89 | IKBKB (0.55) | CHEK1IKBKBJAK2MEN1KMT2A | |
| SCHEMBL1928649 | 0.86 | IKBKB (0.53) | CHEK1IKBKBJAK2MEN1KMT2A | |
| SCHEMBL2933488 | 0.84 | CHEK1 (0.45) | CHEK1IKBKBJAK2MEN1KMT2A | |
| SCHEMBL1929078 | 0.81 | CHEK1 (0.70) | CHEK1IKBKBJAK2MEN1KMT2A | |
| SCHEMBL1928486 | 0.79 | CHEK1 (0.68) | CHEK1IKBKBJAK2MEN1KMT2A | |
| SCHEMBL1926828 | 0.78 | CHEK1 (1.00) | CHEK1IKBKBJAK2MEN1KMT2A | |
| SCHEMBL1928372 | 0.76 | CHEK1 (0.98) | CHEK1IKBKBJAK2MEN1KMT2A | |
| SCHEMBL4070561 | 0.76 | CHEK1 (0.80) | CHEK1IKBKBJAK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243403-A1 | TREATING COLORECTAL, PANCREATIC, AND LUNG CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-08-28 | — | — | US | claimed |
| US-20110152234-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2011-06-23 | — | — | US | claimed |
| EP-1421074-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-09-29 | — | — | EP | claimed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | claimed |
| CN-1263751-C | Novel compounds | ASTRAZENECA AB (SE) | 2006-07-12 | — | — | CN | claimed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | claimed |
| CN-1541214-A | Novel compounds | — | 2004-10-27 | — | — | CN | claimed |
| US-20250281624-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2025-09-11 | — | — | US | disclosed |
| EP-4419104-A2 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | University of Houston System (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118284420-A | Methods and compositions for treating chronic inflammatory lesions, metaplasias, dysplasias, and cancers of epithelial tissue | 休斯敦大学体系 | 2024-07-02 | — | — | CN | disclosed |
| WO-2023239422-A2 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230233691-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2023-07-27 | — | — | US | disclosed |
| US-20140243403-A1 | TREATING COLORECTAL, PANCREATIC, AND LUNG CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-08-28 | — | — | US | disclosed |
| US-20070015819-A1 | Novel compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2007-01-18 | — | — | US | disclosed |
| US-7125896-B2 | Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 | ASTRAZENECA AB (SE) | 2006-10-24 | — | — | US | disclosed |
| CN-1263751-C | Novel compounds | ASTRAZENECA AB (SE) | 2006-07-12 | — | — | CN | disclosed |
| US-20040242573-A1 | Novel compounds | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| CN-1541214-A | Novel compounds | — | 2004-10-27 | — | — | CN | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281624-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MYADM, FABP6 | CHEK1 1581/4885IKBKB 431/4885JAK2 1707/4885 |
| US-20070015819-A1 | Novel compounds | CNR1, ABCG2, CNR2 | CHEK1 3163/4885IKBKB 3173/4885JAK2 166/4885 |
| US-20040242573-A1 | Novel compounds | SULT1E1, TPMT, UGT1A1 | CHEK1 3264/4885IKBKB 2989/4885JAK2 422/4885 |
| US-20230233691-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MYADM, FABP6 | CHEK1 1581/4885IKBKB 431/4885JAK2 1707/4885 |
| US-20110152234-A1 | Novel Compounds | CNR1, ABCG2, CNR2 | CHEK1 3163/4885IKBKB 3173/4885JAK2 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.